MicroRNA 92a-1 (MIR92A1)

MicroRNA 92a-1 (MIR92A1) is a highly conserved, 20–24 nucleotide non-coding RNA encoded as part of the miR-17/92 cluster, which is transcribed by RNA polymerase II, processed by Drosha and Dicer, and incorporated into the RNA-induced silencing complex (RISC). MIR92A1 regulates gene expression post-transcriptionally, influencing cell cycle, proliferation, apoptosis, angiogenesis, and differentiation. It is frequently overexpressed in various cancers and implicated in tumorigenesis, glomerular diseases, cardiovascular, immune, and neurodegenerative disorders. Circulating miR-92a levels serve as promising noninvasive biomarkers in colorectal cancer and kidney diseases. Therapeutic approaches targeting MIR92A1 focus on antisense inhibition or modulation of its upstream regulators, attracting ongoing clinical research in cancer and nephrology.

Other names

hsa-mir-92a-1hsa-mir-92-1MIRN92A1C13orf25MIRN92-1MIR-92-1MIRN92A-1miRNA92-1Putative microRNA 17 host gene proteinMIRHG1microRNA 92-1MIR17HGoncomiR-1

Drugs targeting microRNA 92a-1 typically act by: - Antisense inhibition (anti-miR oligonucleotides) reducing miR-92a activity and restoring expression of direct targets like tumor suppressors or CDK inhibitors, e.g., upregulating p57Kip2 to impair cell proliferation in kidney podocytes. - Modulation of miRNA-related pathways via epigenetic or RNA-editing proteins (e.g., HNRNPA2B1, METTL3).